BPTH logo

Bio-Path Holdings Inc


BPTH: Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.


Show BPTH Financials

Consumer Interest
SEC Filings

Recent trades of BPTH by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BPTH's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: P-ethoxy nucleic acids for stat3 inhibition Jun. 22, 2021
  • Patent Title: Combination therapy with liposomal antisense oligonucleotides Feb. 23, 2021
  • Patent Title: P-ethoxy nucleic acids for liposomal formulation Jan. 26, 2021
  • Patent Title: P-ethoxy nucleic acids for liposomal formulation Jul. 02, 2019
  • Patent Title: P-ethoxy nucleic acids for liposomal formulation Aug. 29, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of BPTH in WallStreetBets Daily Discussion


Recent insights relating to BPTH

CNBC Recommendations

Recent picks made for BPTH stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BPTH

Corporate Flights

Flights by private jets registered to BPTH